Influence Factors and Cognitive Characteristics in Unipolar and Bipolar Depression:Based on the THINC-it Tool

Sponsor
Shanghai Mental Health Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT05053204
Collaborator
(none)
120
1
25.5
4.7

Study Details

Study Description

Brief Summary

Cognitive impairment is the core symptom of unipolar and bipolar depression, which seriously affects the prognosis of the disease and the rehabilitation of social function. There is no unified conclusion in the field and severity of cognitive impairment, and the cause of cognitive impairment is unknown, which may be related to many factors. In this study,the THINC-it tool was used to study the characteristics of cognitive impairment in unipolar and bipolar depression by longitudinal follow-up, which provides a theoretical basis for the differential diagnosis of unipolar and bipolar depression. Early identification and intervention of risk factors can improve the prognosis of the disease.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    there is some cognitive impairment in patients with unipolar and bipolar depression. There is no unified conclusion in the field and severity of cognitive impairment, and the cause of cognitive impairment is unknown, which may be related to many factors. The THINC-it is a simple, fast and free cognitive assessment tool for cognitive impairment screening of unipolar and bipolar depression.

    This study includes three steps.

    1. baseline: demographic data, theTHINC-it tool , clinical scales(HAMD-17,HAMA、YMRS、SDS、PSQI) evaluation and Laboratory examination(blood glucose, blood lipids, BMI)

    2. follow-up (4 week): Clinical scales and THINC-it tool were evaluated in unipolar and bipolar depression.

    3. follow-up (12 weeks): all patients with bipolar depression were evaluated by clinical scales, THINC-it test.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    120 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    Based on the THINC-it Tool to Explore the Characteristics and Related Factors of Cognitive Impairment in the Acute Stage of Unipolar and Bipolar Depression
    Actual Study Start Date :
    May 15, 2021
    Anticipated Primary Completion Date :
    Oct 30, 2022
    Anticipated Study Completion Date :
    Jun 30, 2023

    Arms and Interventions

    Arm Intervention/Treatment
    unipolar depression group

    In accordance with the diagnostic criteria of ICD-10 Unipolar depressive disorder, outpatients or inpatients in the Department of mood Disorders, Mental Health Center of Pudong New area.

    bipolar depression group

    In accordance with the diagnostic criteria of ICD-10 Bipolar depression , outpatients or inpatients in the Department of mood Disorders, Mental Health Center of Pudong New area.

    healthy control group

    Any mental disorder that does not meet the diagnosis of ICD-10, and the society recruits healthy controls who match the sex, age and education level of the patients in the case-group.

    Outcome Measures

    Primary Outcome Measures

    1. the THINC-it Tool [up to 12 week]

      The composite THINC-it tool score is the integrated total score of results from performance on five sub-component cognitive tests of the THINC-it tool.

    Secondary Outcome Measures

    1. Sheehan Disability scale (SDS) [up to 12 week]

      Evaluation of the severity of overall functional impairment

    2. HAMD-17 [up to 12 week]

      Assess the state of depression

    3. HAM-A [up to 12 week]

      Assessing anxiety state

    4. Pittsburgh Sleep Quality Index,PSQI [up to 12 week]

      Evaluate sleep quality

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 60 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    Case group:

    1、Participants in psychiatric outpatients and inpatients are able and willing to provide informed consent.

    1. The participants were male or female aged between 18 and 60, with junior high school education or above.

    2. According to ICD-10 criteria, participants were diagnosed with Unipolar and bipolar depressive disorder.

    3. The total score of Young's Mania scale ((YMRS)) of the participants was less than 5 and HAMD-17 was greater than17.

    4. Subjects received stable mood stabilizers at least two weeks before the study visit, such as SSRIs antidepressants.

    5. The combination or use of supportive psychotherapy is allowed.

    Control group:

    1.it did not meet any of the diagnostic criteria in ICD-10 in the past or at present.

    2.18-60 years old, junior high school education or above. 3.Have sufficient audio-visual skills to complete the necessary examinations of the study.

    4.Willing to participate in this study, and the informed consent form was signed by the subjects.

    Exclusion Criteria:
    1. Current alcohol and / or substance use disorders.

    2. Any drugs that may affect cognitive function, such as psychotropic stimulants, corticosteroids, and receptor blockers.

    3. Benzodiazepines were used within 12 hours and alcohol consumption within 8 hours before using the THINC-it tool.

    4. The patients have some serious physical conditions.

    5. The patients received electroconvulsive therapy ((ECT)) in the past 6 months.

    6. They are serious negative suicidal concepts and behaviors.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Shanghai Mental Health Center IRB Shanghai Shanghai China 200030

    Sponsors and Collaborators

    • Shanghai Mental Health Center

    Investigators

    • Principal Investigator: Jun Chen, M.D., Ph.D, Shanghai Mental Health Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Shanghai Mental Health Center
    ClinicalTrials.gov Identifier:
    NCT05053204
    Other Study ID Numbers:
    • PWRq2021-59
    First Posted:
    Sep 22, 2021
    Last Update Posted:
    Oct 26, 2021
    Last Verified:
    Sep 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 26, 2021